SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mestman JH. Hyperthyroidism in pregnancy. Best Pract Res Clin Endocrinol Metab 2004; 18: 26788.
  • 2
    Weetman AP. Graves' disease. N Engl J Med 2000; 343: 123648.
  • 3
    Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol 1994; 54: 15963.
  • 4
    Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 1994; 84: 9469.
  • 5
    Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 1989; 160: 6370.
  • 6
    Mortimer RH, Cannell GR, Addison RS, Johnson LP, Roberts MS, Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 1997; 82: 3099102.
  • 7
    Diav-Citrin O, Ornoy A. Teratogen update: antithyroid drugs – methimazole, carbimazole, and propylthiouracil. Teratology 2002; 65: 3844.
  • 8
    Clementi M, Di Gianantonio E, Pelo E, Mammi I, Basile RT, Tenconi R. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet 1999; 83: 436.
  • 9
    Di Gianantonio E, Schaefer C, Mastroiacovo PP, Cournot MP, Benedicenti F, Reuvers M, Occupati B, Robert E, Bellemin B, Addis A, Arnon J, Clementi M. Adverse effects of prenantal methimazole exposure. Teratology 2001; 64: 2626.
  • 10
    Koren G, Soldin O. Therapeutic drug monitoring of antithyroid drugs in pregnancy: the knowledge gaps. Ther Drug Monit 2006; 28: 123.
  • 11
    Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk, 8th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2008; 15502.
  • 12
    Wing DA, Millar LK, Koonings PP, Montoro MN, Mestman JH. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 1994; 170: 905.
  • 13
    Greenman GW, Gabrielson MO, Howard-Flanders J, Wessel MA. Thyroid dysfunction in pregnancy. Fetal loss and follow-up evaluation of surviving infants. N Engl J Med 1962; 267: 42631.
  • 14
    Herbst AL, Selenkow HA. Hyperthyroidism during pregnancy. N Engl J Med 1965; 273: 62733.
  • 15
    Mujtaba Q, Burrow GN. Treatment of hyperthyroidism in pregnancy with propylthiouracil and methimazole. Obstet Gynecol 1975; 46: 2826.
  • 16
    Cheron RG, Kaplan MM, Larsen PR, Selenkow HA, Crigler JF Jr. Neonatal thyroid function after propylthiouracil therapy for maternal Graves' disease. N Engl J Med 1981; 304: 5258.
  • 17
    Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group, 1977; 388400.
  • 18
    Holt WA, Talbert LM, Thomas CG Jr, Rankin P. Hyperthyroidism during pregnancy. Obstet Gynecol 1970; 36: 77985.
  • 19
    Goluboff LG, Sisson JC, Hamburger JI. Hyperthyroidism associated with pregnancy. Obstet Gynecol 1974; 44: 10716.
  • 20
    Ghaneim A, Atkins P. Management of thyrotoxicosis in pregnancy. Int J Clin Pract 1998; 52: 368.
  • 21
    Moore KL. The Developing Human; Clinically Oriented Embryology, 4th edn. Philadelphia, PA: WB Saunders Co., 1988.
  • 22
    Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med 1994; 331: 10728.
  • 23
    Aaron HH, Schneierson SJ, Siegel E. Goiter in newborn infant due to mother's ingestion of propylthiouracil. JAMA 1955; 159: 84850.
  • 24
    Friedland DR, Rothschild MA. Rapid resolution of fetal goiter associated with maternal Grave's disease: a case report. Int J Pediatr Otorhinolaryngol 2000; 54: 5962.
  • 25
    Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs 2008; 22: 32534.
  • 26
    Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies (editorial). Teratology 1999; 59: 12.
  • 27
    Behrman RE, Vaughan VC. Nelson Textbook of Pediatrics, 13th edn. Philadelphia, PA: WB Saunders Co., 1987.
  • 28
    Ornoy A, Abir R. Recurrent (habitual) abortions: incidence, epidemiology and possible prevention. In: Issues and Reviews in Teratology, Vol. 7, ed. KalterH. New York: Plenum Press, 1994; 13974.
  • 29
    Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC III, HankinsGDV, ClarkSL. Williams Obstetrics, 20th edn. East Norwich, CT: Appleton & Lange, 1997.
  • 30
    Polak M, Le Gac I, Vuillard E, Guibourdenche J, Léger J, Toubert ME, Madec AM, Oury JF, Czernichow P, Luton D. Fetal and neonatal thyroid function in relation to maternal Graves' disease. Best Pract Res Clin Endocrinol Metab 2004; 18: 289302.
  • 31
    Peleg D, Cada S, Peleg A, Ben-Ami M. The relationship between maternal serum thyroid-stimulating immunoglobulin and fetal and neonatal thyrotoxicosis. Obstet Gynecol 2002; 99: 10403.
  • 32
    Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazol on fetal thyroid status in mothers with Graves hyperthyroidism. J Clin Endocrinol Metab 1997; 82: 36336.
  • 33
    Cohen O, Pinhas-Hamiel O, Sivan E, Dolitski M, Lipitz S, Achiron R. Serial in utero ultrasonographic measurements of the fetal thyroid: a new complementary tool in the management of maternal hyperthyroidism in pregnancy. Prenat Diagn 2003; 23: 7402.
  • 34
    Luton D, Le Gac I, Vuillard E, Castanet M, Guibourdenche J, Noel M, Toubert ME, Léger J, Boissinot C, Schlageter MH, Garel C, Tébeka B, Oury JF, Czernichow P, Polak M. Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 2005; 90: 60938.